Grifols (XMAD:GRF) YoY EPS Growth: 31.42% (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XMAD:GRF Grifols SA XMAD:GRF
86 GF Score
Price €9.54
GF Value €10.53
Valuation Fairly Valued
! 7 Warning Signs
View Full Analysis

What is Grifols YoY EPS Growth?

Grifols XMAD:GRF -1.71% 86 YoY EPS Growth is 31.42% as of Jun. 2026. GuruFocus rates XMAD:GRF with a GF Score™ of 86/100 and a GF Value™ of €10.53 (Fairly Valued). The stock has 7 warning signs investors should review.

YoY EPS Growth is the percentage change of Earnings per Share (Diluted) over the past twelve months. Grifols's YoY EPS Growth for the quarter that ended in Jun. 2026 was 31.42%.

Grifols's Earnings per Share (Diluted) for the three months ended in Jun. 2026 was €0.23.

Grifols YoY EPS Growth Historical Data

* Premium members only.

The historical data trend for Grifols's YoY EPS Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Grifols YoY EPS Growth Chart

Grifols Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
YoY EPS Growth
Get a 7-Day Free Trial Premium Member Only Premium Member Only -69.22 10.39 -79.71 270.14 156.16

Grifols Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
YoY EPS Growth Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 689.91 145.47 42.41 22.21 31.42
XMAD:GRF
86GF Score
Grifols SA XMAD:GRF
YoY EPS Growth is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Grifols YoY EPS Growth Calculation

YoY EPS Growth is the percentage change of Earnings per Share (Diluted) over the past twelve months.

Grifols's YoY EPS Growth for the fiscal year that ended in Dec. 2025 is calculated as:

YoY EPS Growth (A: Dec. 2025 )
=(Earnings per Share (Diluted) (A: Dec. 2025 )-Earnings per Share (Diluted) (A: Dec. 2024 ))/ | Earnings per Share (Diluted) (A: Dec. 2024 ) |
=(0.5907-0.2306)/ | 0.2306 |
=156.16 %

Grifols's YoY EPS Growth for the quarter that ended in Jun. 2026 is calculated as:

YoY EPS Growth (Q: Jun. 2026 )
=(Earnings per Share (Diluted) (Q: Jun. 2026 )-Earnings per Share (Diluted) (Q: Jun. 2025 )) / | Earnings per Share (Diluted) (Q: Jun. 2025 )) |
=(0.2263-0.1722)/ | 0.1722 |
=31.42 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about YoY EPS Growth →
What does a YoY EPS Growth of 31.42% mean?
Grifols (XMAD:GRF) has a YoY EPS Growth of 31.42% as of Jun. 2026. YoY EPS Growth is the percentage change of EPS over the past 12-month. View historical data for Grifols and its competitors.
Is Grifols' YoY EPS Growth too high?
Grifols' current YoY EPS Growth is 31.42%. Overall, Grifols has a GF Score™ of 86/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Grifols' YoY EPS Growth compare to LLY and JNJ?
Grifols' YoY EPS Growth of 31.42% can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good YoY EPS Growth for a Drug Manufacturers company?
A good YoY EPS Growth depends on the Drug Manufacturers industry context. However, YoY EPS Growth should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high YoY EPS Growth mean?
A high YoY EPS Growth can signal that a stock is expensive relative to its fundamentals. YoY EPS Growth is the percentage change of EPS over the past 12-month. View historical data for Grifols and its competitors. Grifols's current YoY EPS Growth is 31.42%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Grifols stock overvalued right now?
Based on GuruFocus' analysis, Grifols (XMAD:GRF) is currently considered Fairly Valued. The stock's GF Value™ is €10.53, compared to a current price of €9.54 — trading 9.4% below its estimated fair value. The current YoY EPS Growth is 31.42%. Grifols' overall GF Score™ is 86/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is YoY EPS Growth calculated?
YoY EPS Growth is calculated from a company's financial statements. For Grifols (XMAD:GRF), the current YoY EPS Growth is 31.42% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Grifols (XMAD:GRF) Overvalued in 2026?

Based on GuruFocus' analysis, Grifols stock appears to be undervalued. The current stock price of €9.54 is trading 9.4% below its estimated GF Value™ of €10.53. GuruFocus considers Grifols to be Fairly Valued.

Key valuation signals for XMAD:GRF:

  • YoY EPS Growth: 31.42%
  • GF Value™: €10.53 vs. price of €9.54 (9.4% below fair value)
  • GF Score™: 86/100 with 7 warning signs

No single metric tells the full story. See the XMAD:GRF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Grifols Business Description

Address Avinguda de la Generalitat, 152-158, Parc de Negocis Can Sant Joan, Sant Cugat del Valles, Barcelona, ESP, 08174
Grifols SA is a Spanish healthcare company specializing in plasma-derived medicines and diagnostic solutions. Its core Biopharma segment develops and sells therapies derived from human plasma, including immunoglobulins, albumin, and coagulation factors used to treat immunodeficiencies, hemophilia, and other chronic conditions. The Diagnostic division provides testing instruments and reagents for blood banking, clinical laboratories, and transfusion medicine. Bio Supplies handles biological products for non-therapeutic uses and plasma sales to third parties, while other activities include manufacturing services and complementary pharmaceuticals. Grifols operates a vertically integrated model, collecting plasma through its own donor centers and processing it into finished therapies. It sells primarily to hospitals, clinics, blood banks, and healthcare providers, generating revenue through product sales and diagnostic services. The company operates across Europe, North America, Latin America, and other international markets, with a significant share of revenue from the United States.
86GF Score

Get the complete analysis for XMAD:GRF

YoY EPS Growth is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€9.54
Price
€10.53
GF Value